Compare Sterling Biotech with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ABBOTT INDIA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ABBOTT INDIA STERLING BIOTECH/
ABBOTT INDIA
 
P/E (TTM) x -0.4 49.9 - View Chart
P/BV x 0.0 16.1 0.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 STERLING BIOTECH   ABBOTT INDIA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ABBOTT INDIA
Mar-19
STERLING BIOTECH/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs118,834 0.1%   
Low Rs35,458 0.1%   
Sales per share (Unadj.) Rs26.81,731.1 1.5%  
Earnings per share (Unadj.) Rs-15.0211.9 -7.1%  
Cash flow per share (Unadj.) Rs-5.5219.9 -2.5%  
Dividends per share (Unadj.) Rs065.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs54.9945.2 5.8%  
Shares outstanding (eoy) m267.8721.25 1,260.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.1 6.3%   
Avg P/E ratio x-0.533.7 -1.4%  
P/CF ratio (eoy) x-1.332.5 -3.9%  
Price / Book Value ratio x0.17.6 1.7%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m1,862151,848 1.2%   
No. of employees `0001.43.5 38.9%   
Total wages/salary Rs m5474,356 12.6%   
Avg. sales/employee Rs Th5,303.310,555.5 50.2%   
Avg. wages/employee Rs Th403.81,249.9 32.3%   
Avg. net profit/employee Rs Th-2,959.01,292.2 -229.0%   
INCOME DATA
Net Sales Rs m7,18136,786 19.5%  
Other income Rs m431,133 3.8%   
Total revenues Rs m7,22337,919 19.0%   
Gross profit Rs m9476,047 15.7%  
Depreciation Rs m2,543169 1,503.1%   
Interest Rs m4,37723 19,453.8%   
Profit before tax Rs m-5,9316,989 -84.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,485 -77.4%   
Profit after tax Rs m-4,0074,503 -89.0%  
Gross profit margin %13.216.4 80.2%  
Effective tax rate %32.435.6 91.2%   
Net profit margin %-55.812.2 -455.8%  
BALANCE SHEET DATA
Current assets Rs m14,33527,610 51.9%   
Current liabilities Rs m49,8098,569 581.3%   
Net working cap to sales %-494.051.8 -954.4%  
Current ratio x0.33.2 8.9%  
Inventory Days Days40360 669.9%  
Debtors Days Days17127 622.9%  
Net fixed assets Rs m55,4321,057 5,244.8%   
Share capital Rs m268213 126.1%   
"Free" reserves Rs m13,93519,873 70.1%   
Net worth Rs m14,70120,086 73.2%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98829,409 251.6%  
Interest coverage x-0.4311.6 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.11.3 7.8%   
Return on assets %0.515.4 3.3%  
Return on equity %-27.322.4 -121.6%  
Return on capital %-6.434.9 -18.4%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,860369 504.1%   
Fx outflow Rs m254,918 0.5%   
Net fx Rs m1,835-4,549 -40.3%   
CASH FLOW
From Operations Rs m1,7194,991 34.4%  
From Investments Rs m-3,148-2,570 122.5%  
From Financial Activity Rs m1,426-1,428 -99.9%  
Net Cashflow Rs m-3993 -0.3%  

Share Holding

Indian Promoters % 33.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 7.9 -  
FIIs % 9.9 0.1 9,900.0%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.1 229.8%  
Shareholders   21,482 18,270 117.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   GSK PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS